ERYTECH strengthens its intellectual property position with the issuance of United States patent for erythrocytes containing arginine deiminase Post author:admERY Post published:September 23, 2015 Post category:Newsroom ERYTECH announces the issuance of a new patent in the United States. You Might Also Like ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020 March 8, 2021 ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line September 8, 2017 ERYTECH Provides Update on the Announced Combination with PHERECYDES May 16, 2023
ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line September 8, 2017